ClinicalTrials.gg
RecruitingNCT07938190lipo-diet_2024Updated Nov 16, 2026

Eating Habits and Behavior in People Affected by Lipodystrophy: Observational Study

An observational study in Lipodystrophy, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

Title: Dietary Habits and Eating Behavior in People with Lipodystrophy: An Observational Study.

Purpose: The purpose of this study is to investigate and analyze the dietary habits and eating behaviors of patients diagnosed with lipodystrophy. Since there is currently a lack of specific data on how these patients approach nutrition, this research aims to provide essential information to improve nutritional guidelines. Additionally, the study seeks to understand if there is a relationship between eating behaviors and the patients' clinical data, such as blood test results and body measurements (anthropometric parameters).

Study Design:

This is an observational, cross-sectional, single-center study with a 2-year enrollment period. Participants will be recruited during their regular medical visits at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.

During the study, the following activities will take place:

Clinical Data Collection: Researchers will record body measurements and blood test results as part of standard clinical practice.

Questionnaires: Patients will be asked to complete four specific questionnaires (available in Italian and English) regarding their food frequency, eating behavior patterns, tendencies toward orthorexia, and physical activity levels.

Format: These questionnaires can be completed electronically via a RedCap link (taking approximately 20-30 minutes) or on paper.

Eligibility:

Inclusion Criteria: Adults (18 years or older) with a confirmed diagnosis of lipodystrophy who provide informed consent.

Exclusion Criteria: Patients with HIV-related lipodystrophy or those who cannot understand the languages in which the questionnaires are provided.

Duration and Participation:

The study will last a total of 2 years and 6 months. The first 2 years are dedicated to patient selection and recruitment, followed by 6 months for data analysis. The researchers aim to enroll 30 participants.

Read the detailed description

1. Background and RationaleLipodystrophy refers to a rare and heterogeneous group of syndromes characterized by the total or partial loss of subcutaneous adipose tissue. This condition leads to severe metabolic complications, such as marked insulin resistance, early-onset diabetes, severe hypertriglyceridemia, and hepatic steatosis (fatty liver).A key factor in this pathology is hypoleptinemia (deficiency of the hormone leptin), which plays a crucial role in regulating energy balance. The lack of leptin disrupts satiety signals, often resulting in hyperphagia (insatiable hunger), with energy intake potentially exceeding requirements by up to 40%. While lifestyle and dietary modifications are considered the "cornerstone" of treatment, there is currently a significant lack of structured data and evidence-based nutritional guidelines for these patients.2. Study ObjectivesPrimary Objective: To identify, analyze, and describe the lifestyle of patients with a focus on dietary habits, eating behaviors, and physical activity.Secondary Objective: To explore the relationship between these behaviors and clinical data, including anthropometric measurements and biochemical (blood) parameters.3. Study Population and EligibilityThe study aims to enroll 30 patients managed at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.Inclusion Criteria: Male and female adults (≥ 18 years old) with a confirmed diagnosis of lipodystrophy who provide written informed consent.Exclusion Criteria: Patients with HIV-related lipodystrophy or those unable to understand the languages in which the questionnaires are provided.4. Study Design and MethodologyThis is a prospective, cross-sectional, observational, single-center study. Data will be collected during routine endocrinological visits through the following means:A. Clinical and Biochemical ParametersAnthropometric Data: Weight, height, BMI, waist and hip circumference, and body fat percentage.Biochemical Data: Fasting plasma glucose, HbA1c, full lipid profile (total cholesterol, HDL, LDL, triglycerides), liver enzymes (AST, ALT), kidney function, insulin levels, and HOMA-IR.B. Self-Assessment QuestionnairesParticipants will complete four validated tools (estimated time: 30 minutes, via RedCap or paper):Food Frequency Questionnaire (FFQ): To assess the intake frequency of 36 food items over the past 12 months.Three-Factor Eating Questionnaire (TFEQ-R18): To evaluate cognitive restraint, uncontrolled eating, and emotional eating.Teruel Orthorexia Scale (TOS): To measure orthorexic tendencies (obsession with healthy eating) in both "healthy" and "nervosa" dimensions.IPAQ-Short Form: To categorize physical activity levels as low, moderate, or high.5. Study Duration and AnalysisThe total study duration is 2 years and 6 months. This includes 2 years for patient recruitment and 6 months for data analysis. Statistical analysis will be performed using STATA 19 SE, comparing the observed dietary data with the 2024 LARN guidelines (Nutrient and Energy Reference Intake Levels) to identify deviations and correlations with metabolic health.

02

Conditions studied

  • Lipodystrophy

Browse trials for

03

In context

Lipodystrophy

140 studies on the registry are indexed under Lipodystrophy; 11 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 35 observational studies indexed under Lipodystrophy.

Browse Lipodystrophy studies →

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 514 studies on the registry; 289 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Male and female patients over the age of 18 attending the outpatient service of the Endocrinology and Diabetes Prevention and Treatment Unit - U. Pagotto - IRCCS AOU in Bologna, Policlinico Sant'Orsola - Malpighi during their visit to the dedicated clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obtaining
  • Age 18 or older at the time of diagnosis
  • Diagnosis of lipodystrophy

Exclusion criteria

Exclusion Criteria:

  • Failure to understand the language in which the questionnaires are administered
  • -related lipodystrophy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Food Frequency Questionnaire (FFQ)

    Time frame: baseline

  2. Three-Factor Eating Questionnaire R-18 (TFEQ-R18)

    Assessment of eating behavior using the 18-item validated questionnaire, evaluating three subscales: Cognitive Restraint (CR), Uncontrolled Eating (UE), and Emotional Eating (EE). Items are scored on a 4-point scale and converted to a 0-100 scale per domain, where higher scores indicate higher expression of the specific behavior.

    Time frame: baseline

  3. Teruel Orthorexia Scale (TOS)

    Time frame: baseline

  4. International Physical Activity Questionnaire - Short Form (IPAQ-Short Form)

    Time frame: baseline

Secondary outcomes

  1. Body Mass Index (BMI)

    Assessment of body weight status using BMI, calculated as weight in kilograms divided by height in meters squared (kg/m2).

    Time frame: baseline

  2. Body Fat Percentage

    Evaluation of total body fat composition measured via anthropometric assessment/bioelectrical impedance analysis (BIA).

    Time frame: baseline

  3. Waist-to-Hip Ratio (WHR)

    Assessment of abdominal obesity calculated as waist circumference divided by hip circumference.

    Time frame: baseline

  4. Fasting Blood Glucose

    Laboratory evaluation of serum/plasma fasting glucose concentration (mg/dL).

    Time frame: baseline

  5. Glycated Hemoglobin (HbA1c)

    Laboratory evaluation of glycated hemoglobin level (mmol/mol).

    Time frame: baseline

  6. Fasting Serum Insulin

    Laboratory evaluation of basal insulin levels micromol/mL.

    Time frame: baseline

  7. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    index score

    Time frame: baseline

  8. Lipid Profile Parameters

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Nov 16, 2026
StartActual
Sep 30, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07938190
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Sep 30, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Carolina Poli, nutritionist
Contact
carolina.poli@aosp.bo.it
0512094676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion